Kornimate/medical-research-clean huggingface dataset:
effects of an educational intervention program on marble factory workers

Conditions: Respiratory Diseases

Summary: marble cutting exposes workers to dust, increasing risk of lung diseases like asthma, copd, silicosis, and asbestosis. many marble cutters in rural areas lack awareness of these risks and work without proper protection. khyber pakhtunkhwa has over 4000 marble factories employing over a million laborers, mostly unskilled and vulnerable. workers face health risks from heavy lifting, poor posture, and respirable dust. ergonomic disorders are also common due to poorly designed workstations, repetitive motions, and straining postures. musculoskeletal symptoms (mss) can progress into musculoskeletal disorders (msds), affecting worker well-being and productivity. findings can inform targeted educational programs and interventions to improve respiratory health and reduce ergonomic risks in the marble industry.

occupational hazards, such as dust exposure during marble cutting, can significantly increase the risk of lung diseases in workers. this includes common ailments such as asthma and chronic obstructive pulmonary disease (copd), as well as more serious conditions such as silicosis and asbestosis. unfortunately, many marble cutters from rural areas may not be aware of these health risks, which can lead to them working without proper protection. heavy load lifting, poor work posture, and the production of respirable dust in marble factories contribute to the health risks faced by these workers. just like dust exposure during marble cutting can harm a worker's lungs, similarly, working in this industry carries a high risk of ergonomic disorders. according to the bureau of labor statistics, ergonomic risk factors are responsible for 35% of workplace injuries in 2021, resulting in msds. an extensive amount of research has been conducted globally; however, limited literature exists on this particular topic in khyber pakhtunkhwa, specifically in peshawar. the findings of the study can help inform the development and implementation of targeted educational programs and interventions aimed at improving respiratory health and reducing ergonomic risks in the marble industry.

Eligibility criteria:
inclusion criteria: * adult male marble factory workers, * age 20-55years * working for more than 1year * working time(hours): minimum 06 hours daily exclusion criteria: * workers with pre-existing lung diseases * workers with any other occupational hazard * workers who are not willing to participate in the study

Keywords: lung function, ergonomic hazards, marble factory workers
hemophilia mobile app usability pilot

Conditions: Hemophilia

Summary: the purpose of this study is to evaluate the utility and user experience of a smart phone app for people with medical conditions, used in conjunction with an actigraph wearable device and a connected scale.

hitlab will conduct a segmented rapid user acceptance study ("rapid ux study") of a smart phone app and an actigraphy device with a connected scale. during the first segment, of one month's duration, subjects will use the app, actigraphy device, and scale. next, over an interphase period of up to 6 weeks, subjects will only use the app. during this time, the app will be modified based on data collected during the first segment. finally, during the second period, also of one month's duration, subjects will use the modified app, actigraphy device, and scale.

Eligibility criteria:
inclusion criteria: 1. you own an iphone or a samsung (s5 or higher) smartphone 2. your age is between 18 and 63 years 3. you reside in the new york metropolitan area 4. you are able to read, write, and speak english 5. you have participated in a concluded clinical trial in the past two years exclusion criteria: 1. you do not own an iphone or a samsung (s5 or higher) smartphone 2. your age is not between 18 and 63 years 3. you do not reside in the new york metropolitan area 4. you are not able to read, write, and speak english 5. you have not participated in a concluded clinical trial in the past two years

Keywords: smartphones clinical trials weight actigraph tracking hemophilia
prone partial breast irradiation (pbi): a prospective randomized trial

Conditions: Breast Cancer

Summary: the purpose of this study is to test whether a radiotherapy regimen of 8 gy x 3 days over 5 days (every other day) is as safe (well-tolerated) and effective as 6 gy x 5 over five consecutive days

despite the fact that less extensive experience than that of brachytherapy is available, pbi delivery through an external-beam has many advantages. first of all, it is likely to be more acceptable to the patient since it is non-invasive and it does not require a surgical procedure or anesthesia. moreover, since it is delivered after surgery, the pathological analysis of the segmental mastectomy specimen is available to inform the selection of the best candidates. in addition, eb-pbi is likely to become more widely reproducible, since it does not rely on the experience and skills of the radiation oncologist performing the brachytherapy implant. besides, once the technique is established, it can be widely applied at any facility provided with a linear accelerator, without the risk presented by some brachytherapy approaches that can not be completed because of the unfavorable interplay of patient's anatomy with the technical limitations of the applicator. the women in this study will receive either 5 or 3 radiation fractions to the tumor bed. we have chosen to study t1 post menopausal women because in this subset: 1) the tumor is small enough to be treated by partial breast radiation 2) the odds of having multicentric disease are low, making it ethical to avoid whole breast irradiation, 3) the most benefit from reducing the radiation schedule from 5 to 3 could be expected. all patients will receive either 8 gy x 3 over 5 days, every other day or 6 gy x 5 over 5 days, on five consecutive days

Eligibility criteria:
inclusion criteria: * post-menopausal women defined as either: 1. at least 2 years without menstrual period 2. patients older than 50 with serological evidence of post-menopausal status 3. hysterectomized patients of any age with fsh confirmation of post- menopausal status * pt1 breast cancer, excised with negative margins. criteria for low risk-ptis: 1. screen-detected 2. low to intermediate nuclear grade 3. \< 2.5cm in size 4. resected with negative margins at \>3mm) * clinically n0 or pn0 or sentinel node negative breast cancer exclusion criteria: * previous radiation therapy to the ipsilateral breast * presence of a proportion of dcis in the core biopsy specimen which is compatible with extensive intraductal component (eic)

Keywords: breast cancer breast cancer prone partial breast irradiation pbi
high versus standard voltage pulsed radiofrequency for cervical nerve roots injection in refractory chronic unilateral cervical radicular pain

Conditions: Chronic Cervical Radiculopathy

Summary: the goal of this interventional study is to compare efficacy of either standard versus supra-voltage radiofrequency cervical epidural injection in pain alleviation in population with chronic cervical radiculopathy.


Eligibility criteria:
inclusion criteria: * age between 20 and 70 years, both genders. * american society of anesthesiologists (asa) physical status grades i or ii. * unilateral cervical radicular pain secondary to cervical disc prolapse affecting single nerve root which was refractory to conventional conservative and physiotherapy measures for 12 weeks or more. * all candidates received 1 millilitre of 2% lidocaine via an ultrasound-guided diagnostic nerve block and informed at least 50% momentary reduction of their pain. * diagnosis was confirmed by cervical mri and nerve conduction tests. exclusion criteria: * refusal to participate. * cervical radiculopathy pain recurrence after surgery. * previous attempt of radiofrequency ablation. * concomitant coagulopathic state ( decompensated liver disease, clopidogrel use) . * metastatic lesion in the cervical vertebral column.
orally fludarabine, adriamycin and dexamethasone (fad) in newly diagnosed peripheral t-cell lymphomas (ptcl)

Conditions: T-Cell Lymphomas; Chemotherapy

Summary: the primary objective of this study is to evaluate the efficacy of fludarabine, adriamycin and dexamethasone (fad) as first line therapy in patients with peripheral t-cell lymphomas (ptcl). 30 patients will be treated into this study.

doxorubicin is often used to treat peripheral t-cell lymphomas (ptcl). however, patients with ptcl have an especially poor outcome with a 5-year overall survival rate of only 26% following treatment with standard doxorubicin containing regimens. there is general agreement that results with conventional chemotherapy are so poor in patients with most ptcl that new approaches are warranted.the nucleoside analogs are fludarabine being combined with other agents in ptcl (excluding alk positive alcl and primary cutaneous alcl) is reported by others.we conduct a ii stage clinical trials to evaluate the efficacy of orally fludarabine, adriamycin and dexamethasone (fad) as first line therapy in patients with in newly diagnosed ptcl.

Eligibility criteria:
inclusion criteria: 1. the diagnosis of peripheral t cell lymphoma must established by histological biopsy, and immunochemistry analysis and cytogenetic assessment should be done as well. the patients with peripheral t cell lymphoma (ptcl), ptcl-unspecified type(ptcl-u), angioimmunoblastic lymphoma (ailt) and non-skin type anaplastic large cell lymphoma (alcl, alk-). 2. aged 18\~75. 3. good performance status, ecog score≤2. estimated survival span \>3 months 4. previously untreated. 5. at least 1 assessable disease (maximal diameter \>1.0cm, the disease foci located within the irradiated area are excluded) evaluated by ct or mri, pet is also permitted. 6. good compliance and inform consenting 7. fit for the following criteria: * absolute neutrophil count (anc)≥1.5×109/l * platelet（plt）≥80×109/l * total bilirubin (tbi) ≤upper normal limit (unl) * serum creatine (cr) ≤unl * alanine aminotransferase (alt) and aspartate transaminase（ast）≤1.5 unl exclusion criteria: 1. severe cardiac, renal or hepatic incompetence: serum direct bilirubin, indirect bilirubin, alt, ast and cr greater than 1.5 unl; cardiac function greater than grade ii. 28 days within the major surgical operation. 2. other malignancy history (skin basement cell carcinoma and cervical carcinoma are excluded) 3. severe uncontrolled underlying diseases 4. pregnancy or lactation 5. autoimmune disease history 6. severe infection or metabolic diseases 7. known allergic to multiple agents, including sulphanilamide. 8. severe peptic ulceration or bleeding, contra-indicative for corticosteroids 9. lymphoma involving central nervous system

Keywords: peripheral t-cell lymphomas (ptcl) fludarabine
longitudinal followup of patients under substitution therapy from the moment they enter a specialized care center for addicts to the period they are monitored by a general practitioner outside the specialized care center

Conditions: Addiction

Summary: this study is part of the french priorities of the 2007-2011 addiction plan. priority #2 of the plan underlines the need to improve practices and access to opioid substitution treatment. priority 3 stresses the importance of articulation and coordination between specialized structures and community medicine to optimize the quality of care and to ensure continuity in the followup of these patients. this study focuses on the followup of patients under substitution therapy from the moment they enter a specialized care center for addicts to the period they are monitored by a general practitioner outside the specialized care center. the assessment described in this study should allow to harmonize and keep a continuity in patient monitoring.


Eligibility criteria:
inclusion criteria: * patients entering a specialized medical care center for addicts exclusion criteria: * patients refusing to sign the consent for participation

Keywords: substitution therapy specialized care center for addicts
an open-label study of zelboraf (vemurafenib) in patients with braf v600 mutation positive metastatic melanoma

Conditions: Malignant Melanoma

Summary: this open-label, single-arm, multicenter study will assess the safety and efficacy of zelboraf (vemurafenib) in patients with braf v600 mutation positive metastatic melanoma. patients will receive zelboraf 960 mg twice a day until progressive disease, unacceptable toxicity, consent withdrawal, death, reasons deemed by the treating physician or study termination.


Eligibility criteria:
inclusion criteria: * adults patients \>= 18 years of age * patients with histologically confirmed metastatic melanoma (surgically incurable and unresectable stage iiic or stage iv; ajcc) with documented braf v600 mutation determined by the cobas® braf v600 mutation test prior to administration of vemurafenib. unresectable stage iiic disease must have confirmation from a surgical oncologist * patients with either measurable or non-measurable disease (recist version 1.1) * patients may or may not have received prior systemic therapy for metastatic melanoma * eastern cooperative oncology group (ecog) performance status of 0, 1 or 2 * patients must have recovered from all side effects of their most recent systemic or local treatment for metastatic melanoma * adequate hematological, renal, and liver function * negative serum pregnancy test at screening * fertile men and women must use an effective form of contraception during the study and for at least 6 months after completion of the study exclusion criteria: * evidence of symptomatic cns lesions as determined by the investigator, use of steroid or anti-seizure medication for treatment of brain metastases prior to the first administration of vemurafenib * patients with previous malignancies (other than melanoma) within the past 2 years except patients with treated and controlled basal or squamous cell carcinoma (scc) of the skin or carcinoma in-situ of the cervix. * concurrent administration of any anti-cancer therapies (e.g. chemotherapy, other targeted therapy, experimental drug, etc.) other than those administered in this study * known hypersensitivity to vemurafenib or another braf inhibitor * pregnant or lactating women * refractory nausea and vomiting, malabsorption, external biliary shunt, or significant bowel resection that would preclude adequate absorption. * any of the following within the 6 months prior to the first vemurafenib administration: myocardial infarction, severe/unstable angina, symptomatic congestive heart failure, cerebrovascular accident or transient ischaemic attack, pulmonary embolism, hypertension not adequately controlled by current medications.
evaluating a caregiver sms reminder intervention to reduce immunization drop-out in arua, uganda

Conditions: Diphtheria; Tetanus; Pertussis; Polio; Measles; Hepatitis B; Haemophilus Influenzae Type b Infection

Summary: faced with high rates of immunization drop-out, uganda's immunization program requires innovative approaches to address this weakness. building upon uganda's growing mhealth infrastructure to pilot a scalable short message service (sms) system to remind caregivers of their children's upcoming vaccination visits, it was hypothesized that the sms intervention will increase immunization coverage in a cost-effective and affordable manner that would make it scalable. the study design was an investigator-blinded, multi-center, parallel groups randomized controlled trial with randomization occurring at the caregiver level in select health facilities of arua district in uganda. enrollment took place at the time of pentavalent 1 vaccination, and both arms included standard of care provided by the health worker. however, in the intervention arm, caregivers also received sms text messages reminding them to return for their children's second and third doses of pentavalent vaccine (four and eight weeks after the first dose of pentavalent vaccine) and measles-containing vaccine (9 months of age). the primary outcome of interest is vaccination coverage at 12 months of age among children enrolled in the study and will be measured by comparing penta3 and mcv coverage between arms. the study will also examine the sms impact on timeliness of vaccine receipt, as it is hypothesized that those children receiving the sms intervention will be more likely to have timely vaccination than those in the control group. the study will also assess caregiver acceptability and cost-effectiveness of the sms intervention. in addition to assessing its impact on strengthening the immunization program, this intervention has implications for strengthening other programs of the health system through similar health messaging directed toward caregivers.


Eligibility criteria:
inclusion criteria: * is a caregiver of a child between the ages of 6 weeks and 6 months of age and presents at one of the study sites for child's penta1 vaccination * access to a personal or household cell phone that can receive text messages * lives in arua district exclusion criteria: * does not have access to the cell phone number at time of registration * does not agree or is unable to consent to participate in the study * does not anticipate being the caregiver through the child's first birthday * plans to move out of arua district in the upcoming year * prior enrollment of the caregiver with a different child

Keywords: sms reminder vaccination immunization vaccination drop-out vaccination timeliness text reminder mhealth cell phone mobile phone
role of preoperative serum thyroglobulin level to differentiate between different thyroid nodules

Conditions: Level of Thyrogobulin in Different Thyroid Nodules

Summary: role of preoperative serum thyroglobulin level to differentiate between different thyroid nodules

incidence of thyroid nodules varies according to the methods of diagnosis, 4-7% by palpation and 17-67% by high resolution ultrasound. the gold standard of diagnosis for thyroid nodules is fine needle aspiration (fna); however, fine needle aspiration cytology (fnac) alone is insufficient to detect cancer because of inadequate cytology (5-15%) and in cases of follicular neoplasm (15-25%) where only surgery is diagnostically conclusive. therefore, other factors in addition to fna should be considered to predict malignancy. this study is done to evaluate the association between elevated pre-operative thyroglobulin levels and histopathologically proven thyroid carcinoma. metabolism of thyroglobulin occurs in the liver and via thyroid gland and recycling of the protein takes place. circulating thyroglobulin features a half lifetime of 65 hours. following thyroidectomy, it will take many weeks before thyroglobulin levels become undetectable. after thyroglobulin levels become undetectable (following thyroidectomy), levels are often serially monitored. a subsequent elevation of the thyroglobulin level is an indicator of recurrence of papillary or follicular thyroid carcinoma. hence, thyroglobulin levels in the blood are mainly used as a tumor marker for certain kinds of thyroid cancer (particularly papillary or follicular thyroid cancer). thyroglobulin is not produced by medullary or anaplastic carcinoma. therefore, this study tries to evaluate the association between the preoperative thyroglobulin levels and thyroid carcinoma proven by post-operative histopathology.

Eligibility criteria:
inclusion criteria: 1. age between 15 to 70 years old 2. patients with solitary thyroid nodules 3. pateints who are fit for surgeries exclusion criteria: * 1_patients who are unfit for surgeries 2_ age below 15 years and above 70 years old 3-patients with thyroid nodule receiving drugs that affect thyroglobulin level as iodine
zinc & bone health in thalassemia: the think zinc study

Conditions: Thalassemia

Summary: the purpose of this study is to test whether zinc can improve bone health in young patients with thalassemia.

the primary aim of this study is to determine if zinc supplementation improves bone health in young patients with thalassemia. osteoporosis is a significant co-morbidity in patients with thalassemia which leads to decreased quality of life. the most effective way to prevent osteoporosis is to build strong, dense bones in the early years. a combination of disease, endocrine and nutritional factors likely contribute to the etiology of osteoporosis in this population. however, even well transfused patients with normal gonadal function who are supplemented with calcium have low bone mass. it is hypothesized that patients with thalassemia have low bone mass, in part, due to zinc deficiency. sub-optimal zinc status has been identified in patients with thalassemia and zinc supplementation has been shown to improve linear growth. to test the primary hypothesis, an 18 month randomized placebo-controlled trial of zinc supplementation (25 mg zn/day) vs. placebo will be conducted in 60 young patients (6-30 yrs) with thalassemia and low bone mass (spine bmd z-score \<-1.0). bone health, as estimated from measurements of bone mass (by dxa and pqct) and markers of bone formation and resorption will be the primary outcome variables. this will be the first study to examine the effects of zinc. supplementation on bone health in patients with thalassemia. if zinc supplementation is found to have a clinically important effect, this simple, safe, non-invasive therapy could quickly become a part of the standard care of these young patients and improve overall health in children and adult patients with thalassemia

Eligibility criteria:
inclusion criteria: * 6 to 30 years of age * thalassemia * bone mineral density z-score \< -1.0 (by dxa) exclusion criteria: * bone marrow transplant recipient * currently prescribed treatment for low bone mass other than calcium or vitamin d (e.g. calcitonin, bisphosphonates) * currently prescribed zinc supplementation who are unable or unwilling to stop during this trial * currently participating in another trial with a medication known to affect bone mineral density. * chronic use of systemic corticosteroids * untreated hypogonadism or growth hormone deficiency * baseline serum copper \< 70 µg/dl * baseline vitamin d-25oh \< 11 ng/ml * pregnant or lactating at study entry

Keywords: zinc, thalassemia, bone mineral density